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http://dx.doi.org/10.1016/j.ccell.2014.11.018SUMMARYCombined BRAF- and MEK-targeted therapy improves upon BRAF inhibitor (BRAFi) therapy but is still beset
by acquired resistance. We show that melanomas acquire resistance to combined BRAF and MEK inhibition
by augmenting or combining mechanisms of single-agent BRAFi resistance. These double-drug resistance-
associated genetic configurations significantly altered molecular interactions underlying MAPK pathway
reactivation. V600EBRAF, expressed at supraphysiological levels because of V600EBRAF ultra-amplification,
dimerized with and activated CRAF. In addition, MEK mutants enhanced interaction with overexpressed
V600EBRAF via a regulatory interface at R662 of V600EBRAF. Importantly, melanoma cell lines selected for
resistance to BRAFi+MEKi, but not those to BRAFi alone, displayed robust drug addiction, providing a poten-
tially exploitable therapeutic opportunity.INTRODUCTION
RAS andBRAF are frequentlymutated in humanmalignancies. In
advanced melanoma, NRAS and, less often, KRAS mutationsSignificance
The understanding that BRAFmutant melanomas frequently a
guided the development of combined BRAF- and MEK-targete
MEK cotargeting is driven by highly tunable-combinatorial mec
dual MAPK pathway targeting. Mechanistic studies highlight V
bases for ERK reactivation. Additionally, we demonstrate that
exquisitely sensitive to acute drug withdrawal. Exploiting mela
tested, via intermittent drug dosing, in the clinic (SWOG/CTEP
240 Cancer Cell 27, 240–256, February 9, 2015 ª2015 Elsevier Inc.occur in 20% of cases and are mutually exclusive with BRAF
mutations, which are present in 50% of cases. Somatic MEK1
or MEK2 mutations, which can be concurrent with RAS or
BRAF mutations, have also been detected (Hodis et al., 2012;cquire BRAFi resistance via MAPK pathway reactivation has
d therapy. Our finding that acquired resistance to BRAF and
hanisms of resistance underscores the intrinsic limitation of
600EBRAF-WTCRAF and V600EBRAF-MUTMEK interactions as
melanoma cells with acquired BRAFi+MEKi resistance are
noma addiction to BRAFi+MEKi for therapeutic gain is being
S1320).
Krauthammer et al., 2012; Nikolaev et al., 2012; Shi et al., 2012a),
but their roles in pathogenesis and therapeutic responses remain
ill defined. BRAF mutations strongly predict responses to ATP-
competitive BRAF inhibitors (BRAFi) such as vemurafenib and
dabrafenib. Allosteric MEK1 and MEK2 inhibitors (MEKi), such
as trametinib, selumetinib, cobimetinib, and binimetinib, may
have antitumor activities against a broader melanoma segment,
including those with NRAS mutations or with both wild-type
(WT) NRAS and WT BRAF, but MEKi monotherapy for patients
with BRAF mutant melanomas is associated with a narrower
therapeutic window (versus BRAFi) (Ribas and Flaherty, 2011).
Melanoma regrowth after initial response to MEKi has been
attributed to a P124LMEK1mutation (Emery et al., 2009), and ac-
quired MEKi resistance in BRAF mutant colorectal cell lines has
been linked to a F129LMEK1 mutation (Wang et al., 2011) or
BRAF amplification (Corcoran et al., 2010). How these MEK mu-
tationsmechanistically account forMEKi resistance is not entirely
clear. Due to the superior clinical benefits of BRAFi formelanoma
patients, mechanisms of acquired BRAFi resistance have been
studied extensively, and those well validated clinically include
NRAS or KRAS mutations (Nazarian et al., 2010; Shi et al.,
2014), V600EBRAF amplification (Shi et al., 2012b) or alternative
splicing (Poulikakos et al., 2011; Shi et al., 2012a), MEK1 or
MEK2mutations (Shi et al., 2012a; Wagle et al., 2011), CDKN2A
loss (Shi et al., 2014), and genetic alterations in the phosphatidy-
linositol 3-kinase-phosphatase and tensin homolog-protein ki-
nase B (PI3K-PTEN-AKT) pathway (Shi et al., 2014; Van Allen
et al., 2014). The convergence of multiple mechanisms to reacti-
vate the mitogen-activated protein kinase (MAPK) pathway pro-
vided a strong rationale for combined BRAF and MEK targeting
to overcome BRAFi resistance, a strategy that is supplanting
single-agent BRAFi therapy. However, acquired resistance to
BRAFi+MEKi still limits the long-term survival of patients with
advanced V600E/KBRAF melanoma. A priori, the intransigence of
acquired resistance in response to dual MAPK targeting may
be due to preferential emergence ofMAPK-redundant resistance
pathways. Evidence of branched evolution, extensive intrapa-
tient aswell as intra- and intertumor heterogeneity, and increased
tumor fitness asmelanomaemerges fromBRAFi-imposed evolu-
tionary selection may help explain why the BRAFi+MEKi combi-
natorial approach is also an ‘‘uphill battle’’ (Shi et al., 2014).
In this study, we investigate the genetic mechanisms of ac-
quired BRAFi+MEKi resistance and elucidate their signaling con-
sequences and therapeutic implications.
RESULTS
Genetic Alterations Underlying Acquired Resistance to
BRAF/MEK Cotargeting in Melanoma
We assembled melanoma tissues with acquired resistance to
BRAFi+MEKi (abbreviated as DD-DP for double-drug disease
progression) (n = 28 DD-DP tumors, each with patient-matched
baseline tumors) from patients (n = 15) treated under two
distinct clinical scenarios (Figure 1A): (1) upfront BRAFi+MEKi
(dabrafenib+trametinib or vemurafenib+cobimetinib) in patients
(n = 10) who were naive to treatment with either BRAFi or MEKi
and (2) BRAFi+MEKi (vemurafenib+cobimetinib) in patients
(n = 5) who had previously responded to but progressed on
BRAFi (vemurafenib) alone (Table S1 available online). We thenCanalyzed known mechanisms of acquired BRAFi resistance in
the MAPK pathway by sequencing the most pertinent exons of
BRAF, NRAS, KRAS, MEK1, and MEK2 and performing BRAF
copy-number analysis (Table S2). Sixteen of 28 DD-DP tumors,
along with their patient-matched baseline tumors and normal tis-
sues (n = 7), were whole exome sequenced and analyzed for
MAPK and PI3K-PTEN-AKT pathway alterations as reported
previously (Shi et al., 2014) (Table S2). In 19 of 28 (68%) DD-
DP tumors, we detected known mechanisms of acquired BRAFi
resistance in the two core resistance pathways. These included
eight DD-DP tumors harboring V600EBRAF amplification, four
harboring NRAS activating mutations, one harboring a KRAS
activating mutation, eight harboring CDKN2A deletions, three
harboring PTEN loss-of-function (LOF) mutation (a substitution
resulting in F127V; Figure S1) or deletions, and one harboring a
PIK3R1 deletion. In contrast to the same alterations detected
in the context of resistance to BRAFi monotherapy (Shi et al.,
2014; Van Allen et al., 2014), those associated with acquired
BRAFi+MEKi resistance were notable for augmented gene
dosage changes, e.g., V600EBRAF ultra-amplification with 74 or
88 copies (Figure 1B; Table S2), LOF F127VPTENmutation (Figure
1C) or homozygous PTEN deletions, G12RNRAS with selective
mutant allele amplification (Figures 1D and 1E), and homozygous
CDKN2A deletions (Table S2). There were examples suggesting
combinatorial mechanisms, e.g., concurrent heterozygous
Q61KNRAS with homozygous CDKN2A deletion and LOF PTEN
mutation; V600EBRAF amplification concurrent with homozygous
CDKN2A deletion or hemizygous DUSP4 deletion (with related
V600EBRAF up-expression and DUSP4 down-expression; Fig-
ures 1F–1H); and homozygous CDKN2A deletion concurrent
with homozygous PTEN deletion and hemizygous PIK3R1 dele-
tion. Thus, genetic analysis of melanomas progressing on
BRAFi+MEKi revealed a prevalence of mechanisms of acquired
BRAFi resistance, but these genetic alterations often occurred in
greater magnitudes or in combinations.
BRAFi-Resistant Melanoma Rapidly Upregulates
Resistance Mechanisms Individually or Combinatorially
to Overcome BRAF/MEK Inhibitors
To further understand acquired BRAFi+MEKi resistance in mela-
noma underlying the two aforementioned clinical contexts, we
generated isogenic human V600EBRAFmelanoma cell lines using
treatment regimens mimicking each clinical context. In the
sequential resistance model, we took those isogenic sublines
with acquired BRAFi (vemurafenib) resistance (single-drug resis-
tance or SDR), via clinically validated mechanisms such as
NRAS mutation (M249R4) (Nazarian et al., 2010), V600EBRAF
alternative splicing (M397R) (Shi et al., 2012b), or amplification
(M395R) (Shi et al., 2012b), and generated further sublines with
BRAFi+MEKi (vemurafenib+selumetinib) or double-drug resis-
tance (DDR). In the upfront BRAFi+MEKi resistance model, we
took the same set of parental (P), drug-naive melanoma cell lines
and treated them at the outset with BRAFi+MEKi until we gener-
ated sublines with DDR (Figure 2A). The cell subpopulations
were exposed to similar increments of inhibitor concentrations,
with the duration at each inhibitor concentration dictated by suc-
cessful population doubling within 3–4 days. When the time-
cumulative doses to reach the full DDR phenotype (defined as
2 mM BRAFi+MEKi) were compared between these two models,ancer Cell 27, 240–256, February 9, 2015 ª2015 Elsevier Inc. 241
Figure 1. Melanomas Resistant to BRAF/MEK Inhibitors Display Exaggerated Genetic Mechanisms of BRAF Inhibitor Resistance
(A) Clinical photos denoting specific genetic mechanisms (red) of drug resistance detected within specific tumors (blue). For patient 9, BRAFi-disease progressive
melanomas responded to BRAFi+MEKi (yellow arrows) on day 14, with disease progression ensuing as evident on day 88.
(B) qPCR and Sanger sequencing of gDNAs extracted frommelanoma samples frompatient 2 and peripheral mononuclear cells (PMN) as a control. The bar graph
shows averages of duplicates.
(C) DD-DPmelanoma frompatient 6 with concurrent heterozygous Q61KNRAS (exomeSeq) and compound heterozygous of K197*PTEN (not shown) and F271VPTEN
(RNASeq). Display by Integrative Genome Viewer with Sanger validation.
(D) G12RNRAS homozygosity in patient 9 DD-DP tumors.
(legend continued on next page)
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it was clear that the development of DDR from SDR was much
faster than DDR directly from P lines (Figure 2A). This observa-
tion is consistent with the hypothesis that preexisting mecha-
nisms of BRAFi resistance could be readily augmented or tuned
up to confer resistance to BRAFi+MEKi.
To assess this hypothesis, we examined the SDR versus SDR-
DDR isogenic pairs of cell lines for alterations in the preexisting,
defined mechanisms of BRAFi resistance (Figures 2B–2E). We
showed that the M397 SDR/DDR progression was associated
with a dramatically upregulated level of alternatively spliced
V600EBRAF mRNA (Figure 2B). Moreover, the M395 SDR/
DDR progression resulted in further V600EBRAF amplification
along with mRNA up-expression. The M249 SDR/DDR pro-
gression upregulated mutant NRAS mRNA levels without
genomic DNA (gDNA) copy-number gain (Figures 2C and 2D).
Accordingly, at the protein expression level (Figure 2E), M249
SDR-DDR expressed an increased NRAS level; M397 SDR-
DDR upregulated the level of a truncated p61 V600EBRAF; and
M395 SDR-DDR upregulated V600EBRAF expression further
(all relative to isogenic SDR sublines). Moreover, full-length
V600EBRAF overexpression (in M395 SDR or SDR-DDR) was
associated with extensive phospho (p)-CRAF levels (versus their
P line). Thus, common mechanisms of acquired BRAFi resis-
tance are highly tunable by either genetic or nongenetic means,
and augmentation or combination of such molecular alterations
readily confers resistance to BRAFi+MEKi.
We then tested whether specific examples of gene dosage
augmentation or concurrent genetic alterations from the exomic
analysis of paired melanoma tissues would augment BRAFi+
MEKi resistance in cell line models. Parallel to the mutant
NRAS amplifications detected in both DD-DPs of patient 9 (Fig-
ures 1D and 1E), M249 SDR-DDR up-expressed mutant NRAS
(albeit via a nonmutational mechanism) (versus P or SDR) (Fig-
ures 2A and 2C–2E). NRAS knockdown (Figure 2F) restored
BRAFi sensitivity to M249 SDR, as would be expected, but it
also strongly restored BRAFi+MEKi sensitivity to M249 SDR-
DDR in both short- and long-term (Figures 2G and 2H) survival
assays, indicating that overexpression of mutant NRAS drove
DDR. To engineer a DDR cell line mimicking Q61KNRAS
heterozygosity+F271VPTEN/K197*PTEN compound heterozygous
mutations (DD-DP of patient 6; Figure 1C), we took advantage
of the PTEN-expressing, Q61KNRAS-driven M238 SDR subline
(Figure 2I), which was derived from its V600EBRAF P line by incre-
mental exposures to increasing doses of BRAFi, and stably
introduced small hairpin (sh)PTEN. We showed that PTEN
knockdown in M238 SDR increased the p-AKT level (Figure 2J)
and resistance to BRAFi+MEKi (Figure 2K), indicating that each
resistance mechanism (Q61KNRAS and PTEN loss) quantitatively
contributed to DDR. Moreover, given that V600EBRAF amplifica-
tion concurred with hemizygous DUSP4 deletion (DD-DP1 and
DD-DP2 of patient 11), we tested whether DUSP4 knockdown
(Figure 2L) could confer DDR to the M395 SDR subline, which
acquired BRAFi resistance via V600EBRAF amplification. As(E) Circos plot showing NRAS copy-number gains in patient 9 DD-DP tumors.
(F) Circos plot showing hemizygous DUSP4 deletions in all three DD-DP tumors
(G and H)DUSP4 (G) and BRAF (H) gDNA copy numbers andmRNA expression le
show ±SD.
See also Figure S1 and Tables S1 and S2.
Cseen in Figure 2M, M395 SDR was moderately cross-resistant
to BRAFi+MEKi treatments, but loss of DUSP4 expression
augmented DDR.
Clonal Analysis Detects Alternative Genetic
Configurations in BRAFi+MEKi Resistance Associated
with MAPK Reactivation
Previous results indicate that once subclones with specific
BRAFi resistance mechanisms have attained clonal dominance,
overcoming BRAFi resistance with the added MEKi is at best an
uphill battle. We then sought to understand the underlyingmech-
anism(s) of resistance to upfront BRAFi+MEKi (vemurafenib+
selumetinib). A polyclonal DDR subline derived from M249
harbored both mutant BRAF ultra-amplification and a MEK1
mutation (F129L) (data not shown). F129LMEK1 had previously
been uncovered in a colorectal subline bred to acquire selume-
tinib resistance (Wang et al., 2011). To understand the individual
contributions of V600EBRAF amplification and MEK1 mutation to
the DDR phenotype, we retreated the M249 P with increments of
BRAFi+MEKi but derived two single-cell-derived M249 DDR
subclones, DDR4 and DDR5. In contrast to M249 P, both
DDR4 and DDR5 were highly resistant to the growth-inhibitory
effect of BRAFi+MEKi in 3-day 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assays (Figure 3A). In fact,
the apparent ‘‘growth stimulation’’ of DDR4 and DDR5 by
BRAFi+MEKi treatment was due to a relative loss of their viability
in the absence of optimal concentrations of the inhibitors. This
‘‘drug addiction’’ phenomenon was even more profound in
long-term clonogenic assays (see Figure 4). SCH772984, an
ERK inhibitor (ERKi) and an analog of which is being tested clin-
ically, was inefficient to inhibit the growth of DDR4 or DDR5 by
itself but was highly active against M249 P (Figure 3A). In fact,
low concentrations of SCH772984 rescued DDR4 and DDR5
from drug addiction, suggesting that suboptimal ERKi dosing
to overcome DDR may paradoxically perpetuate DDR fitness.
In contrast, ERKi restored BRAFi+MEKi sensitivity to DDR4
and DDR5, consistent with MAPK pathway reactivation as the
major mechanism of acquired resistance to upfront BRAFi+
MEKi. This was corroborated by analyzing the MAPK pathway
status (p-ERK levels) in the M249 triplet (Figure 3B). After plating
for 16 hr without both inhibitors, the triplet cell lines were treated
with BRAFi+MEKi (1 hr) at increasing concentrations (Figure 3B)
or with BRAFi+MEKi (1 mM) for increasing durations (up to 72 hr)
(Figure S2A). Western blot analysis showed that DDR4 and
DDR5, compared to M249 P, displayed higher baseline and in-
hibitor-treated p-ERK levels as well as faster p-ERK recovery
in the continued presence of BRAFi+MEKi. Monitoring further
upstream for p-MEK and downstream for p-RSK (T573) levels
revealed a similarly rapid recovery of the MAPK pathway
(Figure S2B).
Consistent with the BRAF protein levels (Figure 3B), we found
that DDR4 harbored V600EBRAF ultra-amplification (47.4-fold
or >160 copies), while DDR5 harbored low copy-numberfrom patient 11.
vels by qPCR and qRT-PCR, respectively, in tumors from patient 11. Error bars
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Figure 2. Melanoma Cells with Acquired BRAFi Resistance Further Resist BRAFi+MEKi by Augmenting Existing or Combining Distinct
Mechanisms
(A) Relative drug exposure times required to achieve resistance to BRAFi+MEKi in three isogenic groups of V600EBRAF melanoma cell lines comparing pro-
gression from SDR/DDR versus P/DDR. [inhibitor], 0.1–2.0 mM.
(B) gDNA and cDNA BRAF copy numbers (average of duplicates) by qPCR or qRT-PCR (top) and by semiquantitative PCR (bottom).
(C) gDNA and cDNA NRAS levels in the M249 P, SDR, and SDR-DDR cell lines in (A) and (B).
(legend continued on next page)
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V600EBRAF gain (4.6-fold or 20 copies) along with F129LMEK1
(Figures 3C and 3D). V600EBRAF copy-number gains quantified
by gDNA quantitative (q)PCR were corroborated by Sanger
sequencing, which showed a BRAF mutant-to-WT ratio of 2:1
in the P line (or about three BRAF copies) and apparent
V600EBRAF homozygosity in DDR4 and DDR5 resulting from
selective V600EBRAF amplification (Figure 3D). Moreover, whole
exome sequence (WES) analysis of the M249 triplet cell lines
confirmed that the DDR-associated altered mutant or variant
allelic frequencies (MAFs) of V600EBRAF and F129LMEK1 (Fig-
ure 3E) were likely due to mutant allele-selective copy-number
gains (Figure 3F). WES analysis also detected a low F129LMEK1
MAF (4%) in the P polyclonal line, suggesting preexistence of
this drug-resistant subclone (Figure 3E). In addition, copy-num-
ber variation (CNV) analysis revealed distinct BRAF amplicons in
M249 DDR4 versus DDR5, suggesting convergent evolution
(Figure 3F, top). Since the concurrence of V600EBRAF amplifica-
tion and F129LMEK1 in M249 DDR5 could be selected by distinct
inhibitor concentrations, we derived two additional M249 DDR
sublines (M249 DDR2 and M249 DDR3) by treatments from the
outset with a higher concentration of BRAFi+MEKi (0.5 mM). In
a pattern suggestive of convergent evolution, both M249 DDR2
and DDR3 displayed low copy-number gains of both V600EBRAF
and F129LMEK1 (Figures S2C–S2E).
Using a WTBRAF cell line, human embryonic kidney 293T
(HEK293T) cells, we then tested the impact of MEK mutants
associated with MAPK inhibitor (MAPKi) resistance on cellular
substrate levels (i.e., p-ERK) and the p-ERK half-maximal
inhibitory concentration (IC50) of MEKi (Figures S2F and S2G).
We overexpressed F129LMEK1, C121SMEK1 (which confers
BRAFi resistance) (Wagle et al., 2011), and several MEK
mutants (Q56PMEK1, K59 delMEK1, and E203KMEK1) associated
with clinical resistance to MAPK targeting and compared
their impacts on baseline p-ERK levels as well as the sensitiv-
ities of p-ERK to MEKi (selumetinib). Although overexpression
of these MEK1 mutants (versus WTMEK1) variably increased
the baseline p-ERK level, their cellular p-ERK IC50 value
to MEKi did not differ appreciably, arguing against allosteric
MEKi binding defect as the shared mechanism of action of
MEK mutants. Their concurrence with V600EBRAF amplification
argues for a possible cooperative biochemical mechanism of
resistance.(D) Sanger sequencing of cDNAs from cell lines in (C) with chromatograms showin
heights).
(E) Western blot (WB) of indicated total and phosphoprotein levels from three iso
nisms. FL, full length; TR, truncated; TUBULIN, loading control. Treatmentswith BR
WB, both short and long exposures shown. Quantification ofWBs for NRAS (M249
(M395 triplet): 1, 10.89, 13.63 (normalization to TUBULIN and then P cell line dat
(F) NRAS knockdown in the M249 SDR and SDR-DDR lines by shRNA as show
shScrambled.
(G) Three-day MTT assays using M249 cell lines from (F). [inhibitor] in micromola
(H) Ten-day clonogenic assays using M249 cell lines from (F). BRAFi or BRAFi+M
(I) cDNA Sanger sequencing showing WT versus mutant NRAS transcripts and t
(J) Stable knockdown of PTEN by lentiviral shRNA in M238 AR (SDR) (BRAFi, 1 mM
cellular lysates 72 hr posttransduction, compared to protein levels in the M238 P
(K) Long-term clonogenic assays of indicated cells from (J).
(L) WB showing the DUSP4 protein levels in control and stable knockdown M39
(M) Three-day MTT assays of indicated cells from (L).
Error bars show ±SEM; n = 5; normalized to DMSO as 100%. BRAFi, vemurafen
CTo further understand the impact of ERKi on survival of DDR4
and DDR5 cells (Figure 3A), we withdrew DDR4 and DDR5 (16 hr
off) from BRAFi+MEKi and then treated them with either ERKi
(1 hr) alone or BRAFi+MEKi+ERKi (1 hr) (Figure 3G). ERKi alone
was ineffective at suppressing the p-ERK rebound following
double-drug withdrawal (Figure 3G). However, once BRAFi+
MEKi was reintroduced, additional treatment with ERKi was
highly effective in suppressing the p-ERK levels (Figure 3G).
Thus, ERKi treatment alone of some melanoma cells previously
selected for resistance by BRAFi+MEKi would be ineffective
unless very high ERKi doses were delivered, which is unlikely
achievable clinically. Thus, clonal M249 DDR4 and DDR5 mela-
noma sublines harbor salient but distinct genetic alterations that
represent tunable and combinatorial modes of resistance to
BRAFi+MEKi reversible by combining ERKi.
Distinct Mechanisms of Resistance Driven
by V600EBRAF Ultra-amplification or V600EBRAF
Amplification+F129LMEK1
Earlier, we noted a robust upregulation of p-CRAF in the M395
SDR and SDR-DDR sublines that harbor V600EBRAF amplifica-
tion (Figure 2E). Hence, we probed the p-CRAF levels in the
M249 triplet lines. DDR4 and DDR5, freshly treated with BRAFi+
MEKi (1 hr), displayed robustly elevated p-CRAF levels (DDR4 >
DDR5 >> P; Figure 3H). Upregulated p-CRAF levels in DDR4 and
DDR5 did not require the continued presence of both inhibitors,
as their withdrawal for up to 20 hr after an overnight (16 hr) treat-
ment did not diminish the p-CRAF levels (Figure S2H). We hy-
pothesized that this strong CRAF upregulation in DDR4 (and a
weaker upregulation in DDR5) may be driven by supraphysio-
logic V600EBRAF overexpression, the degree of which positively
correlated with that of p-CRAF upregulation (Figures 3B, 3H,
and 4A). To test this hypothesis, we knocked down BRAF levels
in DDR4 and DDR5, with or without BRAFi+MEKi, and we found
that BRAF knockdown effectively downregulated p-CRAF levels
(Figure 4A). BRAF knockdown also reduced p-CRAF levels in the
V600EBRAF-amplified M395 SDR-DDR subline (Figure 2B; Fig-
ure S3A). We also knocked down CRAF directly (Figure 4B)
and tested the individual contributions of BRAF versus CRAF
to the clonogenic (i.e., long-term) growth and survival of the
M249 triplet (Figure 4C). As expected, M249 P growth and sur-
vival was not sensitive to CRAF knockdown but highly sensitiveg detection of theWT versus mutantNRAS transcripts (ratio estimated by peak
genic triplets (SDR sublines annotated with known BRAFi resistance mecha-
AFi (SDR) or BRAFi+MEKi (DDR) (1 mM), 16 hr prior to lysate preparation. BRAF
triplet): 1, 0.98, 1.65; for p61BRAF (M397 triplet): 1, 2.55, 7.33; and for FL BRAF
a values set at 1).
n by WB 72 hr after lentiviral infections. Inhibitors were at 1 mM each. shSCR,
r.
EKi treatments every 2 days were started 24 hr after plating.
he estimated ratio in M238 acquired resistant (AR) (SDR) cells.
) showing the levels of indicated phosphoproteins and total proteins by WB of
cell line treated with DMSO. GAPDH, loading control.
5 SDR.
ib; MEKi, selumetinib.
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Figure 3. Melanoma Cells Clonally Develop Resistance to Upfront BRAFi+MEKi via Alternative Genetic Configurations
(A) Three-day MTT assays (error bars show ±SEM, n = 5; top, relative raw values; bottom, normalized to DMSO vehicle as 100%). Cells were plated 16 hr without
inhibitors prior to treatment with indicated inhibitor(s) (in micromolar).
(B) WB of indicated total and phosphoproteins. M249 cell lines were plated 16 hr without inhibitors prior to BRAFi+MEKi treatments for 1 hr (0–10 mM in 10-fold
increments). TUBULIN, loading control.
(C) BRAF copy number by gDNA qPCR (averages of duplicates).
(D) Sanger sequencing showing BRAF and MEK1 mutational status of M249 cell lines.
(E) Integrated Genome View snapshots of reference and mutant reads centered on the A-to-T mutation (chromosome 7:140453136; V600EBRAF) and on the
C-to-G mutation (chromosome 15:66729179; F129LMEK1) in indicated M249 cell lines. Mutat:WT ratios estimated from the MAFs. Note a low MAF of
F129LMEK1 in M249 P.
(legend continued on next page)
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to BRAF knockdown. Consistent with prior short-term assays
(Figure 3A), both M249 DDR4 and DDR5 displayed dramatic
drug addiction. Importantly, in the presence of both inhibitors,
the growth and survival of DDR4 and DDR5 were highly depen-
dent on either CRAF or BRAF, suggesting functional and phys-
ical interaction.
To assess whether there are likely additional genetic under-
pinnings of p-CRAF upregulation (and DDR) in DDR4 and
DDR5, we analyzed the phylogenetic relationship of the M249
triplet (Figure 4D) and assessed the genetic alterations shared
by DDR4 and DDR5 (Table S3). From this WES-based phylog-
eny, it was apparent that DDR4 and DDR5 single-cell clones
represent minor subclones in the P, polyclonal population, since
they each harbored a large number of private mutations, which
escaped detection in the mixed P population. In fact, the num-
ber of shared genetic alterations between DDR4 and DDR5 was
exceedingly small (Table S3), suggesting that these few alter-
ations (aside from V600EBRAF amplification) were unlikely
drivers of DDR. As the M249 P majority population did not har-
bor the DDR4- or DDR5-private mutations, we reasoned that
the ability of salient genetic features shared by DDR2, DDR3,
DDR4, and DDR5 (V600EBRAF amplification) and by DDR2,
DDR3, and DDR5 (F129LMEK1 and its low copy-number gain)
to reconstitute DDR (and their biochemical features) in M249
P would establish sufficiency (in light of necessity established
earlier).
We then directly tested whether supraphysiologic V600EBRAF
overexpression, mimicking the DDR4 and DDR5 levels, would
be sufficient to upregulate p-CRAF levels. We engineered the
M249 P to express stably and homogeneously the empty vector,
F129LMEK1 (Figure 4E), or Q56PMEK1 (Figure 4F), V600EBRAF high
overexpression, and V600EBRAF low overexpression concurrent
with a MEK1 mutation. Regardless of double-drug treatment
(16 hr) or subsequent withdrawal (8 hr), V600EBRAF high
overexpression induced a robust DDR4-like p-CRAF level,
while V600EBRAF low overexpression concurrent with an MEK1
mutation induced a lower, DDR5-like p-CRAF level. Neither
vector control nor MUTMEK1 alone had any impact on the
p-CRAF level. Also, supraphysiologic expression of WTBRAF
or V600E/R509HBRAF (known to disrupt BRAF-CRAF dimerization)
in M249 P only marginally upregulated p-CRAF (Figure 4G).
However, theM249 P engineered cell lines (versus the spontane-
ously resistant DDR4 and DDR5 sublines), displayed a slower
p-ERK recovery (with or without BRAFi+MEKi; Figures 4E
and 4F). This difference (a few hours) was minimal compared
to the extremely slow p-ERK recovery observed in the P line
(not detectable by 3 days; Figure S2A) and appeared to be
due to priorMAPKi exposure or preconditioning,which abolished
the small difference in thep-ERK recovery rate between theM249
P engineered lines versus DDR4 and DDR5 (Figure S3B).
We then assessed the relative potencies of individual alter-
ations observed in M249 DDR4 and DDR5 to confer BRAFi+
MEKi resistance in M249 P using both short-term (Figures S3C
and S3D) and long-term (Figures 4H) survival assays. V600EBRAF(F) CNV display by Circos (with respect to M249 P) showing distinctBRAF amplico
(G and H)WB of indicated total and phosphoproteins fromM249 cell lines plated 1
BRAFi+MEKi cotreatment (1 mM) (G) or prior to BRAFi+MEKi treatment (1 mM, 1
BRAFi, vemurafenib; MEKi, selumetinib; ERKi, SCH772984. See also Figure S2.
Chigh overexpression or V600EBRAF low overexpression concur-
rent with MEK1 mutant (F129L or Q56P) conferred more
than one-log (short-term) or two-log (long-term) increases in
MAPKi resistance. Interestingly, preconditioning of the engi-
neered M249 lines conferred double-drug addiction (Figures
S3E and S3F). As was noted previously for DDR4 and DDR5 sub-
lines (Figures 3A and 4C), the double-drug addiction phenotype
also exaggerated the apparent DDR phenotype of precondi-
tioned M249 P engineered with each genetic configuration
(Figure S3D). These data together (Figures 4E and 4F; Figures
S3B–S3F) thus suggest a mechanistic link between double-
drug addiction and p-ERK rebound (see below in Figure 7).
Moreover, supraphysiologically expressed V600E/R509HBRAF,
defective in p-CRAF induction (Figure 4G), was also compro-
mised in its ability to resist repeated treatments with BRAFi+
MEKi (1 mM, 24 days). V600EBRAF low overexpression or MEK1
mutation alone was individually able to confer BRAFi+MEKi
resistance, but only to an extent appreciably weaker than
achieved by their combination (see growth at 0.1 versus
1.0 mMof drugs at days 15 and 24) (Figure 4H). The combinatorial
effects of overexpressed V600EBRAF and MEK1 mutants on
promoting the DDR phenotype could also be observed in a
different cell line (Figures S3G–S3I). Thus, ERKi-sensitive, ac-
quired resistance to BRAFi+MEKi observed in DDR4 and
DDR5 is causally attributable to either supraphysiologic over-
expression of V600EBRAF or a lower degree of V600EBRAF and
MUTMEK overexpression (Figure 4I; Figure S3). Mechanistically,
excess V600EBRAF proteins promote dimerization with CRAF as
well as CRAF activation and dependency.
Next, to dissect mechanistically how MUTMEK1 aids overex-
pressed V600EBRAF in establishing a full DDR phenotype, we
posited that overexpressed V600EBRAF and MUTMEK physically
and functionally interact in a complex facilitated by (1) the MEK
mutant conformation and (2) a kinase-independent regulatory
role of V600EBRAF. This complex would facilitate MEK phosphor-
ylation and activation by CRAF, akin to a modeled MEK-KSR2-
BRAF regulatory complex (Brennan et al., 2011). Hence, we
tested whether F129LMEK1 in DDR5, but not DDR4, would be
more abundantly associated physically with V600EBRAF. Accord-
ingly, we immunoprecipitated BRAF in the M249 triplet and
probed for MEK1 and MEK2 in the immunoprecipitates. Consis-
tently, much more MEK1 and MEK2 were detected in complex
with BRAF in F129LMEK1-harboring DDR5 (Figure 5A). We then
specifically immunoprecipitated MEK1 and detected a dramati-
cally higher BRAF level bound to MEK1 in DDR5 (Figure 5B).
However, the pattern of BRAF-MEK2 binding was reversed; we
detected more BRAF bound to MEK2 in DDR4 (Figure 5C).
MEK2 in DDR4was also associated with the highest level of acti-
vation-associated phosphorylation at S226, consistent with
MEK2 recruitment to and activation by a BRAF-containing com-
plex. Under the same conditions, we were unable to detect
CRAF or KSR2 in BRAF, MEK1, or MEK2 immunoprecipitates
(data not shown). These data suggest that the supraphysiologic
level of V600EBRAF in DDR4 recruits both WTMEK1 and WTMEK2,ns in DDR4 versus DDR5 (top) andMEK1 copy-number gain in DDR5 (bottom).
6 hr without inhibitors prior to ERKi treatments for 1 hr (0–10 mM)without or with
hr) (H).
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whereas the V600EBRAF level overexpressed to a lesser extent in
DDR5 recruits F129LMEK1 preferentially over WTMEK2.
We also assessed the relative phosphorylation status of MEK1
and MEK2 in DDR4 and DDR5 16 hr after treatment with BRAFi+
MEKi versus M249 P treated with DMSO. Interestingly, we
observed that only DDR4, but not DDR5, harbored an enhanced
level of activation-associated MEK1 and MEK2 phosphorylation
(Figure 5D). In both DDR4 and DDR5, MEK1 displayed increased
levels of ERK-dependent negative feedback phosphorylation on
T291 within its proline-rich region of the kinase domain, which
was not present on MEK2, suggesting that the time-cumulative
ERK activities are far greater in DDR4 and DDR5 despite
BRAFi+MEKi treatment than in P M249. DDR5 harbored the
highest level of p-MEK1 T291, which has been shown to reduce
MEK1-MEK2 heterodimerization and MEK2 S226 phosphoryla-
tion (Catalanotti et al., 2009) and may also explain the reduced
p-MEK1 S222 level (Figures 5D).
We then sought to reconstitute F129LMEK1-V600EBRAF interac-
tion and its functional role in DDR. We had observed that the
majority of MEK1 and MEK2 mutations thus far detected specif-
ically in melanomas with clinically acquired BRAFi, MEKi, or
BRAFi+MEKi resistance (Emery et al., 2009; Shi et al., 2014;
Van Allen et al., 2014; Villanueva et al., 2013; Wagle et al.,
2011, 2014) cluster three dimensionally in or proximal to helices
A and C (Figure 5E; Movie S1). Specifically, in M249 P, we mini-
mally overexpressed a series of FLAG-tagged MEK1 constructs
and coexpressed either hemagglutinin (HA)-tagged WTBRAF or
V600EBRAF, both at high levels akin to DDR5 (Figures 5F and
S4). We then immunoprecipitated protein complexes via FLAG
and detected MEK1, BRAF, and HA levels. Importantly, both
F129LMEK1 and Q56PMEK1, which is homolog to Q60PMEK2, dis-
played dramatically enhanced and preferential interaction with
overexpressed V600EBRAF relative to WTMEK1. Anti-BRAF sig-
nals detected in the FLAG immunoprecipitates presumably con-
tained both endogenous and exogenous V600EBRAF. Thus, these
data support the notion that BRAFi+MEKi treatment in mela-
noma selects forMEK1 orMEK2mutations that impact a discrete
structural subdomain and leads to a conformation favoring phys-
ical association with overexpressed V600EBRAF.
To assess the functional relevance of a V600EBRAF-MUTMEK
complex, we searched for clues of a BRAF-MEK physical inter-
action interface (Figure S5). Based on prior structural dataFigure 4. Achieving BRAF/MEK Inhibitor Resistance via Tuning V600EB
(A) M249 DDR4 and DDR5 plated 16 hr with BRAFi+MEKi (1 mM each), trans
without () inhibitors at 1 mM (1 hr) were analyzed by WB. TUBULIN, loading con
(B) WB for CRAF or BRAF in M249 triplet 48 hr after without () or with (+) CRAF
(C) Cells from (B) plated for clonogenic assays.
(D) Whole exome-based phylogenetic relationships of theM249 triplet cell lines. B
INDELs private to each cell line with respect to the theoretical common ancestra
genes also shown.
(E and F) WB of total and phosphoprotein levels in M249 triplet and M249 P engin
lines treated with BRAFi+MEKi (1 mM) for 16 hr and then washed free of inhibitor
(G) WB analysis of M249 P engineered to express vector, WTBRAF, or V600E/R509H
(H) Clonogenic assays of M249 P engineered to express the indicated levels ofWT
over inhibitor concentrations and time.
(I) Temporal genetic clonal evolution of MAPKi resistance with magnitudes ma
combinatorial genetic alterations proposed as distinct pathways. Distinct V600
subclone.
BRAFi, vemurafenib; MEKi, selumetinib. See also Figure S3 and Table S3.
Cof MEK1-BRAF (Haling et al., 2014), vemurafenib-bound
V600EBRAF (Bollag et al., 2010), and MEK1-KSR2 (Brennan
et al., 2011) and structural alignments of vemurafenib-bound
V600EBRAF with BRAF or KSR2, we hypothesized a regulatory
V600EBRAF-MUTMEK complex where V600EBRAF R662 makes
critical contacts with MEK residues in one complex inter-
face (Figures 6A and 6B). We predicted that the R662L
substitution in V600EBRAF would disrupt this face-to-face
V600EBRAF-MUTMEK interaction and attenuate the DDR pheno-
type. Ectopic expression of vector, HA-WTBRAF, HA-V600EBRAF,
and HA-V600E/R662LBRAF in WTBRAF HEK293T cells revealed
that the R662L substitution did not interfere with the V600EBRAF
kinase activation status in the absence of MAPKi (Figure 6C). We
then engineeredM249 P to stably express a FLAG-F129LMEK1 or
FLAG-Q56PMEK1 along with HA-tagged WT or various mutant
BRAF at levels akin to M249 DDR5 (Figure 6D). After BRAFi+
MEKi treatment (1 mM, 16 hr), anti-FLAG immunoprecipitation
followed by western blots revealed that both MEK1 mutants
most abundantly interacted with V600EBRAF, consistent with
previous results (Figure 5F). Importantly, the R662L mutation in
the context of V600EBRAF strongly abolished this enhanced
V600EBRAF-MUTMEK1 complex and reduced the overall p-ERK
levels. V600E/R509HBRAF also appeared to display reduced
interaction with MUTMEK1 but without a reduction in the p-ERK
levels, suggesting that this apparent reduction was due to loss
of BRAF dimers (Figure 6A) (Haling et al., 2014) or higher-order
oligomers (Nan et al., 2013) brought down by anti-FLAG. Con-
sistently, whereas engineered M249 P lines highly overexpress-
ing V600EBRAF or minimally overexpressing V600E/R509HBRAF
together with a MEK1mutant were able to resist robustly BRAFi+
MEKi at 1 mM, those cell lines expressing V600E/R662LBRAF or
WTBRAF along with an MEK1 mutant grew poorly over 28- or
32-day treatments with BRAFi+MEKi (Figure 6E). Taken together,
these studies (Figures 4, 5, and 6; Figures S3–S5) highlighted a
critical role of upstream MAPK reactivation, i.e., upregulation of
the V600EBRAF-CRAF-MEK complex, in the MAPKi resistance
phenotype. Buildup of this plastic complex is dependent on the
degree of BRAF and/or MEK inhibition and likely other cell
context determinants. In the extreme case of DDR, alternative
mechanisms to upregulate this complex can be achieved by
V600EBRAF (variably overexpressed) interacting with WTCRAF
or with MUTMEK.RAF Gene Dosage with or without MEK Mutations
duced with lentiviral shVector or shBRAF for 48 hr, and treated with (+) or
trol.
or BRAF knockdown, as indicated.
ranch lengths proportional to the number of heterozygous (het) SNVs and small
l cell subpopulation (1). The DDR-unique copy-number variations of indicated
eered to express V600EBRAF and F129LMEK1 (E) or Q56PMEK1 (F). Selected cell
s for 8 hr.
BRAF (without inhibitors) or M249 DDR4 (BRAFi+MEKi, 1 mM, 16 hr).
versusmutant BRAF and/or MEK1 and their relative resistance to BRAFi+MEKi
tching graded selective pressures and with augmented gene dosage versus
EBRAF amplicons indicative of convergent evolution. Each circle, dominant
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Figure 5. Distinct MEK Mutants Share Enhanced Interaction with V600EBRAF
(A–C) The M249 triplet cell lines were plated without (P) or with (DDR4 and DDR5) BRAFi+MEKi (1 mM, 16 hr), and lysates were subjected to immunoprecipitation
(IP) using a control antibody (immunoglobulin G [IgG]) or BRAF (A)-, MEK1 (B)-, or MEK2 (C)-specific antibodies. The IP and total fractions were probed by WB.
TUBULIN, loading control.
(D) WB analysis of total and p-MEK1 and -MEK2 and -ERK levels in the M249 triplet cell lines.
(E) Structure of MEK1 (two views, 180 rotated) with the locations of MEK1 mutations, or residues homologous to MEK2 mutations, indicated in yellow, except
that Q56 and F129 are indicated in green. All mutations, except I111S and P124S, have been detected in melanomas with clinically acquired MAPKi resistance.
(F) M249 P engineered to express vector or FLAG-WTMEK1, FLAG-F129LMEK1, or FLAG-Q56PMEK1 concurrent with overexpression of either HA-WTBRAF or
HA-V600EBRAF were plated with BRAFi+MEKi (1 mM, 16 hr; except vector control), and the lysates were subjected to IP (anti-IgG or -FLAG). WB of IP and total
fractions.
BRAFi, vemurafenib; MEKi, selumetinib. See also Figure S4 and Movie S1.
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Figure 6. A BRAF-MEK Interface Critical for V600EBRAF-MUTMEK1 Interaction and Cooperative DDR
(A) A predicted MEK1 kinase domain (KD)-V600EBRAF KD complex with yellow color highlighting the locations of (1) MEK1 residues mutated in melanomas with
acquired MAPKi resistance; (2) V600EBRAF R509, critical for RAF-RAF dimerization; (3) V600EBRAF R662, structurally homologous to KSR2 A879 critical for MEK1-
KSR2 interaction; and (4) V600EBRAF I617, critical for MEK-BRAF dimerization.
(B) Zoomed-in details of MEK1-V600EBRAF interfaces, highlighting MEK1 activation segment residues (blue: M219, S222, and V224) interacting with V600EBRAF
R662 (yellow), I617 (magenta), and I666 (magenta) and interactions predicted to be abolished by an R662L (red) mutation.
(C) WB of indicated proteins in HEK293T cells transfected with vector or indicated HA-tagged BRAF constructs. TUBULIN, loading control.
(D) M249 P engineered to moderately overexpress HA-BRAF or the indicated BRAFmutants along with either FLAG-MEK1mutant (F129L or Q56P). Experiments
were performed as described for Figure 5F.
(E) Clonogenic assays of M249 P engineered to express WT or indicated mutant BRAF, MEK1 mutants, and/or their empty vectors (Vec). Relative resistance
to BRAFi+MEKi assessed over the indicated concentration range and time points. Three repeats (for 0.1 and 1.0 mM) are shown for the longest time points (28 and
32 days), and growths were quantified (1 mM; n = 3; normalization relative to V600EBRAF+MUTMEK1-transduced cells as 100%; means ± SDs; *p < 0.05, ***p <
0.001, ns, not significant based on ANOVA). BRAFi, vemurafenib; MEKi, selumetinib.
See also Figure S5.Melanoma Cells with Acquired Resistance to
BRAFi+MEKi Display Exquisite Dual Drug Addiction
It has been reported recently that patient-derived xenografts
with acquired resistance to BRAFi driven by V600EBRAF amplifi-Ccation or RNA overexpression could potentially be counterse-
lected during periods of BRAFi withdrawal (Thakur et al., 2013).
We thus tested the degree to which M249 DDR4 and DDR5
were addicted to each (BRAFi or MEKi) or both (BRAFi+MEKi)ancer Cell 27, 240–256, February 9, 2015 ª2015 Elsevier Inc. 251
inhibitors during long-term clonogenic growth. Three days after
seeding, DDR4 and DDR5 cells were kept continuously on
both inhibitors, washed from both, or replenished with only one
of the two inhibitors. Both DDR4 and DDR5 were strongly
addicted to continuous treatment with BRAFi+MEKi (Figure 7A).
The loss of viability after acute BRAFi+MEKi washout could not
be rescued by a dose of ERKi (1 mM) sufficient to strongly sup-
press the rebound in p-ERK resulting from drug withdrawal (Fig-
ure 7B; Figure S6A). Additionally, this ‘‘high’’ dose of ERKi could
resensitize DDR4 and DDR5 to either BRAFi or BRAFi+MEKi,
consistent with prior short-termMTT results (Figure 3A). Notably,
the antigrowth and antisurvival effect of double-drug withdrawal
was comparable to that of ERKi alone or ERKi plus BRAFi (Fig-
ure 7B). However, ERKi at a suboptimal dose (0.1 mM), which
could suppress the rebound p-ERK levels induced by acute
double-drug withdrawal (Figure S6B), completely rescued the
antigrowth and antisurvival effects of BRAFi+MEKi withdrawal
and partially ‘‘erased’’ the antigrowth and antisurvival effects of
single BRAFi or MEKi withdrawal (Figure 7C). Importantly, a sub-
optimal dose of ERKi could be antigrowth and antisurvival only if
DDR4 and DDR5 were continuously treated with BRAFi+MEKi.
We then sought evidence consistent with melanoma regression
in patients who have been discontinued onMAPK-targeted ther-
apies due to disease progression or acquired drug resistance.
From evaluable patients with melanoma who were treated with
BRAFi+MEKi (n = 15) or single-agent BRAFi (n = 16) therapies
(Table S4), we retrospectively collated radiologic images before
and/or during disease progression and compared them to im-
ages, when available or feasible, after a variable time off thera-
pies (Figures S6C and S6D). Although specific clinical examples
of tumor regression after cessation of BRAFi+MEKi therapy
could be identified, overall disease stabilization or uniform tumor
regression leading to clinical remission was not observed. More-
over, only cases of tumor growth deceleration could be observed
for melanomas after cessation of single-agent BRAFi therapy.
Thus, the drug addiction phenotype can be readily elicited in
DDR cell lines only if MAPK inhibition was reversed acutely
and completely, and additional factors maymodulate or mitigate
this phenotype clinically.
Given the strong degree of double-drug addiction noted with
both DDR4 and DDR5, we asked whether this would be
generalizable across different cellular contexts and to mela-
noma cells with acquired resistance to BRAFi treatment alone.
Interestingly, we found that melanoma cell lines adapted to
growth with BRAFi+MEKi far more consistently displayed
drug addiction (Figure 7D). Also consistent was the observation
that melanoma cell lines with DDR displayed a greater rebound
in p-ERK levels after drug washout (Figure 7E). This greater
rebound was not necessarily due to the maximal p-ERK levels
upon withdrawal of drugs but rather due to the very low p-ERK
levels in the presence of both drugs (i.e., stronger on-target
pathway suppression). Quantification of the fold changes in
p-ERK levels (Figure 7E) and in clonogenic growths (Figure 7D)
showed that they are strongly negatively correlated. Thus,
melanoma cells with DDR displayed a stronger rebound in
p-ERK levels and drug addiction upon drug withdrawal, when
compared to melanoma cells with single-drug resistance with-
drawn from BRAFi (Figure 7F). This p-ERK rebound is indicative
of drug addiction since a suboptimal dose of ERKi could rescue252 Cancer Cell 27, 240–256, February 9, 2015 ª2015 Elsevier Inc.cells from double-drug withdrawal-induced loss of fitness
(Figure 7C).
DISCUSSION
The understanding of how BRAF mutant melanomas frequently
acquire BRAFi resistance via several distinctmechanisms, which
thematically reactivate the MAPK pathway, has provided foun-
dational rationale to combined BRAF/MEK inhibition to suppress
suchmechanisms. The ensuing translational effort has led to this
combination supplanting BRAFi monotherapy in the clinic. This
study of genetic alterations in melanomas with acquired BRAFi+
MEKi resistance has provided unexpected insights. First, we
detected alterations affecting similar genes known to be respon-
sible for acquired BRAFi resistance, which suggests that the
gene dosage or concurrence of these mutations may impart
altered molecular interactions promoting BRAFi+MEKi resis-
tance. The exaggerated genetic configurations encompassed
gain-of-function (e.g., V600EBRAF ultra-amplification, G12RNRAS
amplification) and LOF (e.g., F127VPTEN, deletions affecting
PTEN, CDKN2A, DUSP4) alterations, and their combinations.
Second, focusing on MAPK reactivation, we uncovered a
highly plastic or tunable RAF-MEK complex resulting frommuta-
tions (single-nucleotide variants [SNVs] and/or CNVs). For
instance, supraphysiologic levels of V600EBRAF allosterically
relay oncogenic MAPK signaling via back-to-back interactions
with CRAF. Moreover, moderately overexpressed levels of
V600EBRAF likely regulate MEK1 and MEK2 activation via a
face-to-face complex. These altered molecular interactions
underscore an intrinsic limitation of combined BRAF andMEK in-
hibition and predict potential limitations of further downstream
inhibitors (e.g., ERKi) in overcoming acquired BRAFi+MEKi
resistance.
Thus, we have shown how (1) quantitative genetic alterations
or gene dosage impact qualitative modes of signaling and (2)
combinatorial alterations might be selected to impact survival
signaling cooperatively (Figure 8). MEK1 and MEK2 mutants
with alterations residing in or proximal to the helices A andC sub-
structures share an increased ability to form an activation-asso-
ciated complex with V600EBRAF, especially when both BRAF and
MEK mutants are moderately overexpressed. Moreover, a
proposed MUTMEK-V600EBRAF heterodimer interface strongly
suggests that such a face-to-face physical interaction involves
predominantly a kinase-independent or regulatory function of
V600EBRAF. Together, these data indicate a V600EBRAF-CRAF-
MEK signaling complex that is highly susceptible to upregulation
via single or multiple convergent genetic (and likely nongenetic)
alterations.
Our study of melanoma cell lines with acquired resistance to
combined BRAF and MEK inhibition has revealed insights into
recent clinical studies. For instance, melanoma cell lines with pre-
existing BRAFi resistance augment preexisting mechanisms
quickly as they adapt to combined BRAF and MEK inhibition.
This is consistent with the clinical observation that patients who
progressedonBRAFiorMEKimonotherapies infrequently respond
to the addition of the other inhibitor, and, for thosewho do respond
sequentially, the responses are generally highly transient. Further-
more, the importanceof anMAPKi resistance-relatedcomplexhas
certain translational implications. Successful strategies targeting
Figure 7. Resistance to Combined BRAF/MEK Inhibition Results in Exquisite Drug Addiction
(A) Clonogenic survival ofM249 DDR cell lines plated in BRAFi+MEKi, 1 mMeach, for 72 hr and then cultured for 9 days with or without specific inhibitor withdrawal
(representative of three independent repeats).
(B and C) Clonogenic assays as in (A) except for the indicated high (B) or low (C) ERKi doses starting at 72 hr after plating.
(D) Clonogenic assays comparing SDR versus DDR cell lines of distinct genetic backgrounds and resistance mechanisms. amp, amplification; spl, splicing.
(E) WB analysis of p-ERK levels without or with acute BRAFi (SDR) or BRAFi+MEKi (DDR) withdrawal for 4 and 24 hr. TUBULIN, loading control. Quantification of
p-ERK signals normalized to TUBULIN levels is shown for each cell line relative to the baseline signals (no inhibitor withdrawal).
(F) Correlation between changes in p-ERK levels (E, 4 versus 0 hr) and in clonogenic growths (D) upon inhibitor(s) withdrawal.
BRAFi, vemurafenib; MEKi, selumetinib; ERKi, SCH772984. See also Figure S6 and Table S4.
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Figure 8. Alterations in a V600EBRAF-CRAF-
MEK Complex with Opposite Impacts on
Melanoma Fitness Contingent on the Pres-
ence of BRAF and MEK Inhibitors
Alternative configurations of an RAF-MEK resis-
tance-related complex consisting of (1) a supra-
physiologic level of V600EBRAF, which activates
CRAF, or (2) a moderately overexpressed
V600EBRAF level concomitant with a mutant
MEK1 (or MEK2), which leads to increased
V600EBRAF-MUTMEK interaction. Both signaling
configurations strongly favor ERK activation,
leading to growth and survival finely tuned to the
BRAFi+MEKi level. Paradoxically, acute removal
of BRAFi+MEKi disrupts this fine-tuning and re-
sults in a p-ERK rebound favoring cell arrest and
death (i.e., drug addiction). WT (gray) and mutant
(red) proteins; blue circles, BRAFi or MEKi.this tunable-combinatorial signalingcomplexmay include those in-
hibiting CRAF function (e.g., omni- or pan-RAF inhibitors),
V600EBRAF-CRAF interaction, V600EBRAF-MUTMEK interaction or
scaffolding, and MEK activation (e.g., phosphorylation by RAF).
These strategies could be built around continued inhibition of
mutant BRAF and MEK or alternating regimens. In our studies,
the efficacy of an ERK inhibitor in overcoming acquired BRAFi+
MEKi resistancewas nuanced and depended on the experimental
contexts, e.g., ERKi alone at lower concentrations promoted sur-
vival and growth of BRAFi+MEKi-resistant melanoma cells in
both short- and long-term assays.
While the buildup of a V600EBRAF-CRAF-MEK complex ulti-
mately limited the efficacy of combined BRAF andMEK inhibition
in melanoma, this signaling complex appeared to be poised
to deliver a lethal dose of signaling once both inhibitors were
efficiently and acutely removed (Figure 8). Melanoma cells with
fully acquired BRAFi+MEKi resistance were much more sensitive
to drug withdrawal than those with acquired resistance to BRAFi
alone. It is possible that in vivo factors, such as tumor hetero-
geneity (e.g., subpopulations with reversible drug tolerance but
without drug addiction), 3D cell-cell contacts, microenviromental
signals, and/or host pharmacokinetic considerations, could
render drug addiction a clinically intractable phenotype. In this
light, the hypothesis of intermittent therapy with combined BRAFi
andMEKi todelayacquired resistancewill be testedprospectively
within a large randomized clinical trial (SWOG/CTEP S1320) for
the treatmentofpatientswithBRAFmutantmetastaticmelanoma.EXPERIMENTAL PROCEDURES
Patients, Tumor Samples, and Genomic Analysis
Melanoma tissues and patient-matched normal tissueswere collectedwith the
approval of institutional review boards at University of California, Los Angeles;254 Cancer Cell 27, 240–256, February 9, 2015 ª2015 Elsevier Inc.University of California, San Francisco; and Van-
derbilt-Ingram Cancer Center and informed con-
sents of each patient. Patients were enrolled in
GlaxoSmithKline or Roche/Genetech clinical trials
or treated per standard clinical management. We
evaluated 45 tumor samples (27 DD-DP, 4 DP,
and 14 baseline or early on-treatment melanoma
biopsies) from 14 patients who were either treated
with BRAFi+MEKi upfront or with this combinationafter progression on BRAFi. In each tumor, genetic mechanisms (excluding
PI3K-PTEN-AKT genetic hits) known to confer clinical resistance to BRAFi
were detected by gDNA qPCR and/or Sanger sequencing. Twenty-three
baseline and DD-DP tumors from seven patients along with normal tissues
were WES analyzed to detect somatic alterations that are in the MAPK and
PI3K-PTEN-AKT pathways and that are specific to drug-resistant tumors.
Pair-end sequences with read length of 2x100 base pairs using the Illumina
HiSeq2000 platform were generated. SNVs, insertion-deletions (INDELs), and
CNVs were analyzed and visualized as described previously (Shi et al., 2014).
Targeted Sequencing, Copy-NumberQuantification, andWESofCell
Lines
BRAF,NRAS, andDUSP4cDNA levelswerequantifiedby real-timeRT-PCRus-
ing TUBULIN and GAPDH levels for normalization. Relative expressions were
calculated using the delta-Ctmethod. BRAF,NRAS, andDUSP4 gDNA relative
copy numbers were quantified by real-time PCR with total gDNA content esti-
mated by assaying the b-globin gene in each sample. All primer sequences
are available upon request. Sanger sequencing was performed using purified
PCR via BigDye v1.1 (Applied Biosystems) in combination with a 3730 DNA
Analyzer (Applied Biosystems). WES of M249 triple cell lines were analyzed
for shared and distinct genetic alterations and their phylogenetic relationship.
Cell Culture, Constructs, Infections, and Transfections
All cell lines were maintained in DMEM with 10% heat-inactivated fetal bovine
serum, 2mmol/l glutamine in a humidified 5%CO2 incubator, with the addition
of 10 ng/ml doxycycline and/or puromycin, when applicable. Stocks and dilu-
tions of PLX4032/vemurafenib (Plexxikon), AZD6244/selumetinib (Selleck
Chemicals), and SCH772984 (Merck) were made in DMSO. Cell proliferation
experiments were performed in a 96-well format (five replicates per sample),
drug treatments were initiated 24 hr postseeding for 72 hr, and cell survival
was quantified using CellTiter-GLO assay (Promega). Clonogenic assays
were performed by plating cells at single-cell density in six-well plates
with fresh media and drug replenished every 2 days. Colonies were fixed in
4% paraformaldehyde and stained with 0.05% crystal violet. shBRAF,
shCRAF, shPTEN, and shNRAS were subcloned into the lentiviral vector
pLL3.7; shDUSP4/pLK0.1 vectors were obtained commercially (Dharmacon).
All WT and mutant MEK1 and BRAF constructs were epitope tagged and
subcloned into the doxycycline-repressible lentiviral vector pLVX-Tight-Puro
(Clontech Laboratories). Viral supernatants were generated by third-genera-
tion lentiviral packaging using HEK293T cells. HEK293T cells were transfected
using BioT (Bioland).
Protein Detection, Interaction, and Structure
Cell lysates were made in radioimmunoprecipitation assay buffer (Sigma) for
direct western blotting or in a PNE buffer (PBS:H2O at 1:1, 0.5% Nonidet
P-40, 5mMEDTA, and 5%glycerol) for immunoprecipitation, with both buffers
supplemented with protease (Roche) and phosphatase (Santa Cruz Biotech-
nology) inhibitor cocktails. Western blots and immunoprecipitations were per-
formed using the following antibodies: p-ERK1/2 (T202/Y204), p-MEK1/2
(S217/221), p-AKT (T308), p-CRAF (S338), total ERK1/2, MEK1/2, MEK1,
MEK2, AKT, CRAF, DUSP4, and HA (Cell Signaling Technology); TUBULIN
and FLAG (Sigma); BRAF (F-7), BRAF (C-19), p-MEK1 (T291), and p-MEK1
(S222) (Santa Cruz); and p-MEK2 (S226) (United States Biological). Western
blot quantification was performed using NIH ImageJ. The 3D structures of
MEK1 (3EQC) and PTEN mutants were modeled by the I-TASSER online
server. Modeling the V600EBRAF-MUTMEK1 dimer interface was based on the
crystal structure of the WTBRAF-WTMEK1 dimer (4MNE); the MEK1-KSR2
dimer (2Y4I); and the asymmetric, vemurafenib-bound V600EBRAF dimer
(3GO7). Protein structures were visualized using PyMol (DeLano Scientific).
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